Tirzepatide is a prescription medicine that acts on two hormone receptors in the body, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). In Australia it is sold under the brand name Mounjaro and is used for type 2 diabetes and, in eligible adults, for chronic weight management.
It can help control blood sugar and affects appetite, how full you feel, and how much you eat. Tirzepatide is given as an injection once a week, with the dose usually raised gradually if appropriate. It is not a form of insulin.
Common side effects include nausea, diarrhoea, vomiting, constipation, and stomach discomfort. It is not suitable for everyone and needs a prescription plus ongoing monitoring. Before starting and during treatment, a doctor should review other medicines, contraception, plans for pregnancy, and any upcoming surgery.
Book a telehealth consultation with an AHPRA-registered GP for assessment, prescriptions, referrals or advice.
Book ConsultationTirzepatide is a weekly injectable medicine for type 2 diabetes and weight management that acts on two gut hormone receptors.
No. This glossary explains general health terminology, not your individual symptoms or test results. Speak with a qualified health professional for advice about your circumstances. For a medical emergency, call 000.
Proudly Australian-owned and operated